Stongbridge Biopharma to be acquired by Xeris Pharmaceuticals
Irish company valued at $267 million ahead of buyout by American pharma firm
Xeris Pharmaceuticals, the US pharma company with a market cap of $217 million, announced it is to acquire Stongbridge Biopharma, the Irish public limited company.
As part of the deal, Strongbridge has been valued at $267 million.
The merger aims to create a leading company in endocrinology and rare diseases with a pipeline of drug development. Strongbridge develops and commercialises therapies for people with rare diseases and significant unmet needs.
The new, merged entity will ...
